Clinical trials: Hemochromatosis
Blood Disease, Hemochromatosis
Statistical Basis for Hemochromatosis Screening
To determine optimal values for transferrin saturation for use in population screening for hereditary hemochromatosis.
- Trial name
- NCT00005559
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Idiopathic Pulmonary Hemosiderosis, Leflunomide
Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children
The goal of this clinical trial is to compare Leflunomide in Idiopathic pulmonary hemosiderosis. The main questions it aims to answer are: The efficacy and safety of Leflunomide in Idiopathic pulmonary hemosiderosis The mechanism…
- Trial name
- Lef for IPH (NCT05937191)
- Testing
- Leflunomide, Steroid Drug
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hereditary Hemochromatosis, Hyperferritinemia
Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.
Iron overload in hereditary hemochromatosis (HH) is treated by phlebotomy. It is unclear, if individuals with hyperferritinemia due to hereditary hemochromatosis or to secondary causes are suitable as blood donors.
- Trial name
- NCT05742035
- Testing
- Venipuncture
- Where
- 2 sites in Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Interregionale Blutspende SRK
Iron Overload, Thalassemia Major
"Iron Overload and Endocrinological Diseases"
Patients with hemochromatosis or Thalassemia develop progressive tissue and organs damages secondary to iron overload. Iron overload can result both from transfusional hemosiderosis and excess gastrointestinal iron absorption.
- Conditions
- Iron Overload, Thalassemia Major, Thalassemia Intermedia, Hemochromatosis
- Trial name
- NCT06137079
- Where
- Italy
- Volunteers
- 62 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Sickle Cell Disease
Liver Fibrosis in Sickle Cell Disease
Patients with sickle cell disease many have a number of systemic complications, including liver problems. Some of these liver problems lead to liver fibrosis/cirrhosis, secondary to chronic blood transfusions.
- Trial name
- NCT02007746
- Testing
- Liver transient elastography (Fibroscan), Ferriscan, Liver biopsy in iron overloaded subjects.
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Miami
Anemia, Sickle Cell, Transfusion Hemosiderosis
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Hypothesis: The investigators suspect that significant degrees of iron overload in subjects with SCD result in decreased red cell survival, abnormal endothelial function and markedly dysregulated autonomic function.
- Trial name
- NCT00981370
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Hospital Los Angeles
Chronic Anemia, Transfusional Hemosiderosis
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
The overall purpose of this trial is to further evaluate the efficacy and safety of deferasirox, dosed initially according to the transfusional iron intake, in patients with transfusion dependant anemia related to disorders other…
- Trial name
- NCT00631163
- Testing
- Deferasirox (ICL670)
- Where
- 31 sites in Japan, Poland and 3 more
- Volunteers
- 102 people
- Sponsor
- Novartis Pharmaceuticals
Hemochromatosis, Cerebrovascular Accident
Stroke With Transfusions Changing to Hydroxyurea
The purpose of this study is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with…
- Conditions
- Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
- Trial name
- NCT00122980
- Testing
- Red Cell Transfusions, Iron Chelation, Hydroxyurea
- Where
- 28 sites in United States
- Volunteers
- 134 people
- Sponsor
- St. Jude Children's Research Hospital
Hereditary Hemochromatosis C282Y Homozygous
HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 Hemochromatosis
HFE(High iron FE)-related hereditary hemochromatosis has a highly variable penetrance. No phenotypic or genetic markers can predict the disease.
- Trial name
- HEPFER (NCT01784939)
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Rennes University Hospital
Hemosiderosis
Pharmacogenetic Study in Patients Received Iron Chelating Agent
To investigate effect of genetic variations on the toxicities and find optimal target population, the investigators planned to analyze the genetic polymorphisms of UDP-glucuronosyltransferase.
- Trial name
- NCT01623895
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Iron Metabolism Disorders, Iron Overload
Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement
Polyphenolic compounds are very strong Inhibitors of non-heme iron absorption, as they form insoluble complexes with ferrous iron.
- Conditions
- Iron Metabolism Disorders, Iron Overload, Polyphenols
- Trial name
- NCT03990181
- Testing
- meal matrix & NPPS, meal matrix & CS, no-matrix & NPPS
- Where
- 2 sites in Portugal, Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
Hemochromatosis
Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
Comparison of efficacy and toxicity of the combination treatment of deferiprone and desferrioxamine with the single agent treatment of either drug
- Trial name
- NCT00350662
- Testing
- Deferiprone (L1), Desferrioxamine
- Where
- 2 sites in Egypt, Turkey (Türkiye)
- Volunteers
- 95 people
- Sponsor
- Lipomed
Hemochromatosis
Haemochromatosis and Periodontitis
Periodontitis is a chronic inflammatory disease that affects tissues surrounding the teeth. It is strongly associated with the major pathogenic "red complex", including Porphyromonas gingivalis, Tannerella forsythia and Treponema…
- Trial name
- HEMOPARO (NCT04006249)
- Testing
- dental probes
- Where
- France
- Volunteers
- 87 people
- Sponsor
- Rennes University Hospital
Hereditary Hemochromatosis
A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis
This study will be conducted in two parts run in parallel. Part 1 of the study (Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose) will enroll healthy volunteers in 3 sequential dose escalating…
- Trial name
- NCT07371793
- Testing
- BBI-001
- Where
- Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bond Biosciences
Hemochromatosis Type 1
Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis
Hemochromatosis type 1 is one of the most frequent genetic disease since the genetic predisposition (homozygosity for the C282Y mutation of the HFE gene) is encountered in about 3/1000 white subjects (5/1000 in Brittany, France).
- Trial name
- SAIFER (NCT01810965)
- Testing
- First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Rennes University Hospital
Transfusional Hemosiderosis
Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox
This study will observe patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.
- Trial name
- NCT01394029
- Testing
- deferasirox
- Where
- 10 sites in Egypt, Jordan and 2 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Iron Overload
Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
This study employed a prospective, single-arm, global multi-center interventional open-label, non-randomized design to identify and assess safety profile of the crushed deferasirox FCT when administered up to 24 weeks in…
- Trial name
- MIMAS (NCT03372083)
- Testing
- Deferasirox
- Where
- 10 sites in Egypt, Italy and 5 more
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Iron Overload, HFE-Associated Hereditary Hemochromatosis
Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis
Hereditary haemochromatosis (HHC) is a frequent disease in Brittany (5 to 7‰), responsible first for biological disorder in blood iron parameters and minor clinical disorders, before evolving to potential life-threatening…
- Trial name
- HEMOCOEUR (NCT02099214)
- Testing
- 3Tesla cardiac MRI, Electrocardiogram (EKG), Iron and cardiac markers
- Where
- France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Hemochromatoses, Genetic
Transferrin Saturation and Asthenia in Hemochromatosis
Observational study.
- Trial name
- HEMOSAT (NCT03356548)
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Rennes University Hospital
Hereditary Haemochromatosis
Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?
Haemochromatosis is a preventable genetic iron overload disorder. Untreated, it can shorten life due mainly to liver cirrhosis and cancer. It can be prevented by blood donation to maintain normal iron levels.
- Trial name
- Mi-iron (NCT01631708)
- Testing
- Erythrocytapheresis, Plasmapheresis
- Where
- 3 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute